Solving the Puzzle of Cognitive Problems Caused By HIV Infection

Key points
- A longstanding medical mystery – why so many people with HIV experience memory loss and other cognitive problems despite potent antiretroviral therapy – may have been solved by researchers at Albert Einstein College of Medicine of Yeshiva University.
- Even though antiretroviral treatment suppresses HIV replication and slows the progress of HIV disease, between 40 and 60 percent of HIV-infected people eventually develop mild-to-moderate neurological deficits, and up to 5 percent develop full-blown dementia.
- In a previous study, the Einstein researchers found that HIV infects about 5 percent of brain cells known as astrocytes.
- The evidence came from a laboratory model of the blood-brain barrier constructed of human cells and from examining brain tissue of macaque monkeys infected with the simian form of HIV.
A longstanding medical mystery – why so many people with HIV experience memory loss and other cognitive problems despite potent antiretroviral therapy – may have been solved by researchers at Albert Einstein College of Medicine of Yeshiva University. Their findings are published in the June 29 issue of The Journal of Neuroscience.
Even though antiretroviral treatment suppresses HIV replication and slows the progress of HIV disease, between 40 and 60 percent of HIV-infected people eventually develop mild-to-moderate neurological deficits, and up to 5 percent develop full-blown dementia. Until now, researchers have not been able to explain why these complications, collectively known as neuroAIDS, occur.
In a previous study, the Einstein researchers found that HIV infects about 5 percent of brain cells known as astrocytes. These cells bolster the blood-brain barrier, a network of blood vessels that prevents harmful substances from crossing into the brain from the bloodstream. In the present study, the researchersshow that even this low-level of astrocyte infection can profoundly damage the blood-brain barrier.
"The relatively few infected astrocytes emit toxic signals through specialized channels that kill neighboring uninfected astrocytes, ultimately weakening the blood-brain barrier and allowing harmful compounds to enter the brain,” said senior author Joan Berman, Ph.D., professor of pathology and of microbiology & immunology at Einstein.
The evidence came from a laboratory model of the blood-brain barrier constructed of human cells and from examining brain tissue of macaque monkeys infected with the simian form of HIV. The results suggest that drugs capable of reducing the damaging signaling cascades triggered by HIV-infected astrocytes might help in preventing or treating neuroAIDS.
The Journal of Neuroscience paper is titled "Human Immunodeficiency Virus Infection of Human Astrocytes Disrupts Blood–Brain Barrier Integrity by a Gap Junction-Dependent Mechanism." The paper''s lead author is Eliseo Eugenin, Ph.D., assistant professor of pathology at Einstein.
###
Albert Einstein College of Medicine of Yeshiva University
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Infections, HIV & STIs →
News'Dual source' caused Aids-like virus
A genetic study of SIV - the Aids-like virus that infects monkeys - suggests that HIV - the virus that causes Aids in humans - came about through the combination of two viruses in chimpanzees. Chimps could have been…
1 January 2003
NewsWhen and Who can get a coronavirus vaccine?
Federal government officials are promising coronavirus vaccines soon - some even before Christmas - and states are gearing up to begin vaccinating Americans sometime in December. It almost sounds as if people will be…
2 December 2020
NewsNHS England needs to stop stalling and make HIV preventing treatment available
An effective treatment that can prevent HIV infection and reduce the human and financial costs of the preventable condition is taking too long to be commissioned and made available on the NHS, warns Deborah Gold, chief…

